Faculty & Staff Details

	Name:	Xinli Liu
	Position:	Assistant Professor
	Email:	xinli.liu@ttuhsc.edu
	Bio	Dr. Liu joined the Pharmaceutical Sciences faculty as an Assistant Professor. She received a B.S. in Chemistry from Lanzhou University (China; 1999) and earned her Ph.D. at the University of Kentucky (2004). Her doctoral research focused on the liposomal delivery of the prodrugs of the anti-cancer agent camptothecin. She also employed mass spectrometry as a tool to study drug metabolism and DNA adducts as a potential biomarker for disease processes. She completed a postdoctoral fellowship in clinical pharmacology at the Institute of Pediatric Clinical Research, Division of Hematology and Oncology at Children’s Hospital Los Angeles, University of Southern California (2007). She studied pharmacology of the anti-cancer agent retinoids in preclinical models.

Education:

Postdoctoral Fellow Children’s Hospital Los Angeles, University of Southern California, 2007
Ph.D. University of Kentucky, 2004
B.S. Lanzhou University, China, 1999

Research Interests:

Chemotherapy is an important approach in the treatment of human cancer. Many conventional anticancer drugs do not discriminate between cancerous and normal cell types and were consequently accompanied by dose limiting toxic side effect. Our main research interest is to develop molecularly targeted nanocarrier systems such as nanoparticles and liposomes to improve tumor drug delivery while avoiding healthy cells.

Current Grant Support:
North and Central Texas Clinical and Translational Science Initiative Pilot Grant Award, 2009

Publications:

Liu X, Lynn BC, Zhang J, Song L, Bom D, Du W, Curran DP, Burke TG. A Versatile Prodrug Approach for Liposomal Core-Loading of Water-Insoluble Camptothecin Anticancer Drugs. Journal of the American Chemical Society. 2002 Jul 3; 124(26):7650-1

Liu X, Zhang, J, Song L, Lynn BC, Burke TG. High Performance Liquid Chromatography-Electrospray Ionization-Tandem Mass Spectral Analysis of the Degradation Products of Camptothecin-20-Glycinate Ester Pro-Drug Analogs in Aqueous Solution and Human Blood. Journal of Pharmaceutical and Biomedical Analysis, 2004, Sep 3; 35(5):1113-25

Liu X, Lovell MA, Lynn BC. Development of a Method for Quantification of Acrolein-deoxyguanosine adducts in DNA using isotope dilution-capillary LC/MS/MS and its application to human brain tissue. Analytical Chemistry. 2005, Sep 15; 77(18): 5985-9

Liu X, Lovell MA, Lynn BC. Detection and Quantification of Endogenous Cyclic DNA Adducts Derived from trans-4-Hydroxy-2-nonenal in Human Brain tissue by Isotope Dilution Capillary Liquid Chromatography Nanoelectrospray Tandem Mass Spectrometry. Journal of the Chemical Research in Toxicology. 2006, May, 19(5): 710-8


Posters and Presentations
D. Bom, J. Zhang, S. Kruszewski, X. Liu, T. G. Burke, “Core loaded liposomal DB-67” Poster in 2001 AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications. 2001, Miami Beach, Florida.

T. G. Burke, X. Liu, J. Zhang, L. Song, R. Bevins, D. Bom, S. G. Zimmer, “A versatile pro-drug approach for the liposomal core loading of camptothecin anticancer drugs” Poster in 2002 AACR Annual Meeting, 2002, San Francisco, CA.

T. G. Burke, X. Liu, J. Zhang, L. Lopez-Barcons, R. Perez-Soler, “Pre-clinical pharmacology and development of liposomal formulations of the potent topoisomerase I inhibitor DB-67” Poster in ASCO's 38th Annual Meeting, 2002, Orlando, Florida.

X. Liu, T. Fragala, Y. Kim, V. Maldonado, B.J. Maurer, C.P. Reynolds, “Intracellular concentrations of fenretinide obtained in neuroblastoma murine subcutaneous xenografts are lower than achieved in cell culture and limited xenograft responses”. Poster in 2005 AACR-NCI-EORTC international Conference Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications. 2005, Philadelphia, Pennsylvania.

X. Liu, V. Maldonado, T. Fragala, B.J. Maurer, C.P. Reynolds, “Subcutaneous tumor exposure to fenretinide in neuroblastoma murine xenografts is below most tissues and potentially limits tumor response”. Poster in Advances in Neuroblastoma Research meeting, 2006, Los Angeles.

X. Liu, B.J. Maurer, T. Fragala, J.G. Page, N.E. Patricia, R. Rulton, M. M. Ames, J. M. Reid, S. Gupta, R. Vishnuvajjala, J.E. Tomaszewski, and C.P. Reynolds. “Preclinical Toxicity and Pharmacokinetics of Intravenous Lipid Emulsion Fenretinide.” Poster in 2007 AACR-NCI-EORTC international Conference Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications . 2007, San Francisco, CA.